Ligand validation:8FQM

YDB: 1-[(2R)-2-{2-[(5-amino-1,3,4-thiadiazol-2-yl)sulfanyl]acetamido}-2-boronoethyl]-1H-1,2,3-triazole-4-carboxylic acid

YDB is a Ligand Of Interest in 8FQM designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8FQM_YDB_B_401	82%	17%	0.089	0.945	2.39	1.44	7	2	0	0	100%	1
8FQM_YDB_A_403	71%	11%	0.104	0.926	2.32	2.09	6	2	0	0	100%	1
8FQM_YDB_D_401	64%	13%	0.11	0.908	2.52	1.62	8	2	1	0	100%	1
8FQM_YDB_C_401	58%	19%	0.12	0.9	2.47	1.18	8	2	1	0	100%	1
8FQW_YDB_B_401	67%	14%	0.114	0.924	2.69	1.34	7	2	3	0	100%	1
8FQQ_YDB_B_502	64%	6%	0.11	0.907	2.71	2.45	8	2	0	0	100%	1
8FQU_YDB_B_401	93%	15%	0.07	0.963	2.42	1.56	7	2	0	0	100%	1
8FQS_YDB_B_401	74%	16%	0.105	0.935	1.65	2.22	4	3	2	0	100%	1
8FQO_YDB_B_401	53%	3%	0.151	0.911	2.73	3.53	8	2	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.